Role of tacrolimus combination therapy with mycophenolate mofetil in the prevention of organ rejection in kidney transplant patients

P. Dalal, G. Shah, D. Chhabra, Lorenzo Gallon*

*Corresponding author for this work

Research output: Contribution to journalReview article

6 Scopus citations

Abstract

Several new medications are now available for immunosuppression in the kidney transplant field. Tacrolimus and mycophenolate mofetil were first introduced for immunosuppression in renal transplantation in the mid 1990s. Since then, the combination of tacrolimus and mycophenolate mofetil has been evaluated in numerous clinical trials. The outcomes of these trials have varied due to differences in induction and/or maintenance therapy, drug dosing and monitoring protocols, and study design. The aim of this review is to analyze the literature critically and to provide an overview of tacrolimus and mycophenolate mofetil combination therapy in renal transplantation.

Original languageEnglish (US)
Pages (from-to)107-115
Number of pages9
JournalInternational Journal of Nephrology and Renovascular Disease
Volume3
StatePublished - Aug 18 2010

Keywords

  • Immunosuppression
  • Kidney transplantation
  • Mycophenolate mofetil
  • Tacrolimus

ASJC Scopus subject areas

  • Nephrology

Fingerprint Dive into the research topics of 'Role of tacrolimus combination therapy with mycophenolate mofetil in the prevention of organ rejection in kidney transplant patients'. Together they form a unique fingerprint.

  • Cite this